GO:0003865 3-oxo-5-alpha-steroid 4-dehydrogenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0003865 describes the enzymatic activity that converts a 3-oxo-5-alpha-steroid to a 3-oxo-delta(4)-steroid using an acceptor, a reaction catalyzed by steroid 5-alpha-reductase enzymes.
• The reaction is central to androgen metabolism, converting testosterone to the more potent dihydrotestosterone (DHT) in prostate and other tissues.
• SRD5A1, SRD5A2, and SRD5A3 are the principal human genes encoding 3-oxo-5-alpha-steroid 4-dehydrogenase activity, with distinct tissue distributions and substrate preferences.
• Altered 5-alpha-reductase activity is implicated in benign prostatic hyperplasia, prostate cancer progression, and hormone-refractory disease.
• Enzyme activity is modulated by phosphorylation state and phospholipid environment, indicating post-translational and membrane-lipid regulation.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable precise dissection of SRD5A gene function in steroid metabolism and disease.
Description
3-oxo-5-alpha-steroid 4-dehydrogenase activity (GO:0003865) is a molecular function defined as the catalysis of the reaction: a 3-oxo-5-alpha-steroid + acceptor = a 3-oxo-delta(4)-steroid + reduced acceptor. This activity is synonymous with steroid 5-alpha-reductase and is responsible for the NADPH-dependent reduction of the double bond at the 4-position of steroid substrates, a key step in androgen biosynthesis and catabolism. The reaction is best known for converting testosterone into dihydrotestosterone (DHT), a more potent androgen that drives prostate growth and contributes to benign prostatic hyperplasia and prostate cancer. Researchers study GO:0003865 because it sits at the intersection of endocrinology, oncology, and developmental biology. The enzyme activity is not limited to mammals; bacterial homologs such as Comamonas testosteroni 3-ketosteroid-delta4(5-alpha)-dehydrogenase have been characterized, providing evolutionary and mechanistic insights. In mammals, the activity is developmentally regulated in tissues such as the epididymis, where it influences sperm maturation and steroid hormone balance. Dysregulation of 3-oxo-5-alpha-steroid 4-dehydrogenase activity has been linked to hormone-refractory prostate cancer, where the type-3 isozyme SRD5A3 is overexpressed. Pharmacological inhibition of this activity is a therapeutic strategy in prostate disease, and expression of markers such as NKX3.1 can support intervention in active surveillance. Understanding the enzymatic mechanism, its regulation by phosphorylation and membrane lipids, and its genetic control is therefore essential for developing targeted therapies.
3-oxo-5-alpha-steroid 4-dehydrogenase activity At A Glance
| GO ID | GO:0003865 |
|---|---|
| GO term | 3-oxo-5-alpha-steroid 4-dehydrogenase activity |
| Ontology | molecular_function |
| Synonym | steroid 5-alpha-reductase; 3-oxo-5alpha-steroid delta4-dehydrogenase; testosterone 5alpha-reductase; 4-ene-3-ketosteroid-5alpha-oxidoreductase activity |
| Major function | Catalyzes the conversion of a 3-oxo-5-alpha-steroid to a 3-oxo-delta(4)-steroid using an acceptor, key in androgen metabolism |
| Reaction | a 3-oxo-5-alpha-steroid + acceptor = a 3-oxo-delta(4)-steroid + reduced acceptor |
| Cofactor | NADPH or NADH as electron donor (acceptor is typically NADP+) |
| Subcellular location | Membrane-associated, particularly endoplasmic reticulum and nuclear envelope |
| Representative genes | SRD5A1, SRD5A2, SRD5A3 in humans; bacterial homologs such as Comamonas testosteroni 3-ketosteroid-delta4(5-alpha)-dehydrogenase |
What Is GO:0003865?
In simple terms, GO:0003865 is the enzyme activity that removes a hydrogen from a steroid molecule and rearranges a double bond, using an acceptor molecule in the process. The official definition is: Catalysis of the reaction: a 3-oxo-5-alpha-steroid + acceptor = a 3-oxo-delta(4)-steroid + reduced acceptor. This activity is also known as steroid 5-alpha-reductase, 3-oxo-5-alpha-steroid delta4-dehydrogenase, and testosterone 5-alpha-reductase, among many synonyms. It belongs to the molecular_function ontology aspect and is characterized by the conversion of a saturated 5-alpha-steroid to a delta(4)-steroid, a reaction that requires an electron acceptor such as NADP+.
Why Is 3-oxo-5-alpha-steroid 4-dehydrogenase activity Important in Cell Biology?
3-oxo-5-alpha-steroid 4-dehydrogenase activity is critically important because it controls the production of dihydrotestosterone (DHT), the most potent natural androgen, which drives prostate cell proliferation and is a central mediator of benign prostatic hyperplasia and prostate cancer. The enzyme also participates in the inactivation and clearance of other steroids, influencing hormone balance in peripheral tissues. Its developmental regulation in the epididymis highlights roles in male fertility and sperm maturation. Moreover, the activity is modulated by phosphorylation and membrane phospholipids, making it a sensitive node for cellular signaling and a target for pharmacological intervention. In cancer, overexpression of the SRD5A3 isozyme is associated with hormone-refractory prostate cancer, suggesting that this activity contributes to resistance to androgen deprivation therapy.
• Converts testosterone to dihydrotestosterone (DHT), the primary androgen driving prostate growth.
• Implicated in the pathophysiology of benign prostatic hyperplasia and benign prostatic enlargement.
• Overexpression of SRD5A3 is linked to hormone-refractory prostate cancer.
• 5-alpha-reductase inhibition is used in prostate cancer active surveillance, supported by markers like NKX3.1.
• Developmental regulation in the epididymis affects sperm maturation and male fertility.
• Enzyme activity is modulated by phosphorylation state, linking it to cellular signaling.
• Phospholipid environment influences epididymal 5-alpha-reductase activity, indicating membrane-dependent regulation.
• Bacterial homologs provide model systems for studying the catalytic mechanism.
• The activity is a target for drugs such as finasteride and dutasteride in prostate disease.
• Genetic variants in SRD5A2 cause 5-alpha-reductase deficiency, a disorder of sex development.
What Happens During 3-oxo-5-alpha-steroid 4-dehydrogenase activity?
Substrate binding and recognition
In simple terms: The enzyme grabs a steroid molecule that has a specific shape, like a lock fitting a key.
The reaction begins with the binding of a 3-oxo-5-alpha-steroid substrate, such as testosterone, to the active site of the enzyme. The enzyme recognizes the 3-keto group and the saturated A-ring, positioning the substrate for hydride transfer. This step is stereospecific and requires the correct orientation of the steroid nucleus. In mammals, different isozymes (SRD5A1, SRD5A2, SRD5A3) exhibit distinct substrate preferences and tissue distributions, influencing which steroids are processed.
Hydride transfer and double bond formation
In simple terms: The enzyme removes a hydrogen pair and creates a double bond in the steroid ring.
The catalytic mechanism involves the transfer of a hydride from the substrate to an electron acceptor, typically NADP+, resulting in the formation of a double bond between C4 and C5 of the steroid A-ring. This converts the 5-alpha-steroid to a delta(4)-steroid. The reaction is irreversible under physiological conditions and is dependent on the presence of an appropriate acceptor. The bacterial enzyme from Comamonas testosteroni has been shown to catalyze a similar dehydrogenation, confirming the conserved chemistry.
Product release and acceptor recycling
In simple terms: The newly made steroid is released, and the used acceptor is recycled back.
After the reaction, the 3-oxo-delta(4)-steroid product, such as dihydrotestosterone, is released from the active site. The reduced acceptor (e.g., NADPH) must be re-oxidized by cellular metabolism to sustain catalytic cycles. The enzyme operates in a membrane environment, and product release may be influenced by the lipid composition of the membrane. This step ensures that the enzyme can process multiple substrate molecules.
Tissue-specific and developmental regulation
In simple terms: The enzyme's activity changes depending on the tissue and the stage of development.
The activity of 3-oxo-5-alpha-steroid 4-dehydrogenase is not uniform across tissues. In the rat epididymis, enzyme activity fluctuates during development, peaking at specific postnatal stages, which correlates with the onset of sperm maturation. In the prostate, the activity is higher in hyperplastic tissue, contributing to DHT-driven growth. These patterns are controlled by hormonal and developmental signals, including androgens themselves.
Post-translational modulation
In simple terms: Chemical tags on the enzyme can turn its activity up or down.
The activity of rat liver 3-oxo-5-alpha-steroid 4-dehydrogenase is modulated by changes in its phosphorylation state, indicating that kinases and phosphatases can regulate the enzyme. Additionally, the phospholipid environment of the membrane can alter epididymal 5-alpha-reductase activity in vitro, suggesting that lipid composition is a regulatory factor. These mechanisms allow rapid adjustments to steroid metabolism in response to cellular signals.
Key Genes Involved in GO:0003865 3-oxo-5-alpha-steroid 4-dehydrogenase activity
The following genes encode proteins that exhibit 3-oxo-5-alpha-steroid 4-dehydrogenase activity or are directly involved in its regulation and downstream effects.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SRD5A1 | Encodes steroid 5-alpha-reductase type 1, a membrane enzyme that converts testosterone to DHT | Expressed in skin and liver; studied for role in androgen metabolism and drug targeting |
| SRD5A2 | Encodes steroid 5-alpha-reductase type 2, the predominant isozyme in prostate | Mutations cause 5-alpha-reductase deficiency; target of finasteride in BPH and prostate cancer |
| SRD5A3 | Encodes steroid 5-alpha-reductase type 3, overexpressed in hormone-refractory prostate cancer | Linked to cancer progression and resistance to androgen deprivation |
| NKX3.1 | Prostate tumor suppressor and androgen-regulated transcription factor | Expression supports 5-alpha-reductase inhibition intervention in active surveillance |
| AR | Androgen receptor, mediates DHT signaling | Downstream effector of 5-alpha-reductase activity; studied in prostate cancer |
| CYP17A1 | Cytochrome P450 17A1, involved in androgen biosynthesis | Upstream of 5-alpha-reductase in steroidogenic pathway |
| HSD3B2 | 3-beta-hydroxysteroid dehydrogenase, converts precursors to androgens | Provides substrates for 5-alpha-reductase |
| AKR1C3 | Aldo-keto reductase, contributes to androgen synthesis | Alternative pathway for DHT production in castration-resistant prostate cancer |
| Comamonas testosteroni 3-ketosteroid-delta4(5-alpha)-dehydrogenase | Bacterial homolog of 5-alpha-reductase | Model for enzyme mechanism and evolution |
| SRD5A2 (rat) | Rat epididymal 5-alpha-reductase | Developmental regulation studies |
| SRD5A1 (rat liver) | Rat liver 3-oxo-5-alpha-steroid delta4-dehydrogenase | Phosphorylation-dependent modulation studies |
| Phospholipid environment | Membrane lipids that modulate enzyme activity | In vitro regulation of epididymal 5-alpha-reductase |
| NADPH | Electron donor for the reduction reaction | Cofactor required for catalytic activity |
| NADP+ | Electron acceptor in the reverse reaction | Product of the dehydrogenase reaction |
| Testosterone | Substrate for 5-alpha-reductase | Converted to DHT; central to androgen action |
| Dihydrotestosterone (DHT) | Product of 5-alpha-reductase activity | Potent androgen driving prostate growth |
| Finasteride | Pharmacological inhibitor of SRD5A2 | Used to treat BPH and prostate cancer |
| Dutasteride | Dual inhibitor of SRD5A1 and SRD5A2 | Therapeutic agent for prostate disease |
How Is 3-oxo-5-alpha-steroid 4-dehydrogenase activity Regulated?
The activity of 3-oxo-5-alpha-steroid 4-dehydrogenase is regulated at multiple levels. Post-translational modification by phosphorylation can modulate enzyme activity, as shown for the rat liver enzyme. The phospholipid environment of the membrane also influences activity, with in vitro studies demonstrating that changes in lipid composition alter epididymal 5-alpha-reductase activity. Hormonal regulation, particularly by androgens, affects expression levels in tissues such as the prostate and epididymis. Developmental cues control the timing and magnitude of activity in the epididymis. In cancer, overexpression of SRD5A3 in hormone-refractory prostate cancer suggests that transcriptional or post-transcriptional mechanisms contribute to dysregulation.
3-oxo-5-alpha-steroid 4-dehydrogenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SRD5A2 | Benign prostatic hyperplasia; 5-alpha-reductase deficiency | SRD5A2 knockout mouse; point-mutation knock-in of deficiency variants |
| SRD5A3 | Hormone-refractory prostate cancer | SRD5A3 overexpression in prostate cancer cell lines; xenograft models |
| NKX3.1 | Prostate cancer active surveillance | NKX3.1 knockout or overexpression in prostate organoids |
| SRD5A1 | Androgen metabolism in skin and liver | SRD5A1 knockout mice; tissue-specific conditional KO |
| AR | Androgen insensitivity; prostate cancer | AR point-mutation knock-in; AR knockout models |
Benign prostatic hyperplasia (BPH)
BPH is a common condition in aging men characterized by prostate enlargement. The pathophysiology involves increased dihydrotestosterone (DHT) production, which is driven by 3-oxo-5-alpha-steroid 4-dehydrogenase activity. Inhibition of this enzyme with 5-alpha-reductase inhibitors reduces prostate size and symptoms, confirming the central role of this activity in BPH.
Prostate cancer
Prostate cancer is androgen-dependent in its early stages, and DHT, the product of 5-alpha-reductase, promotes tumor growth. Overexpression of SRD5A3, a type-3 5-alpha-reductase, is observed in hormone-refractory prostate cancer, suggesting that this isozyme contributes to resistance to androgen deprivation therapy. Adjunct screening of NKX3.1 expression has been proposed to support 5-alpha-reductase inhibition intervention in active surveillance.
5-alpha-reductase deficiency
Mutations in the SRD5A2 gene cause 5-alpha-reductase deficiency, a disorder of sex development characterized by impaired conversion of testosterone to DHT. This condition highlights the essential role of 3-oxo-5-alpha-steroid 4-dehydrogenase activity in male sexual differentiation.
Male fertility and epididymal function
The epididymis requires precise steroid hormone balance for sperm maturation. Developmental changes in 5-alpha-reductase activity in the rat epididymis suggest that this enzyme influences fertility and sperm function. Modulation of enzyme activity by phospholipids further indicates that membrane environment affects reproductive physiology.
From 3-oxo-5-alpha-steroid 4-dehydrogenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of SRD5A2 reduce DHT levels and prostate growth? | SRD5A2 knockout mouse or prostate-specific conditional KO |
| How do point mutations in SRD5A2 affect enzyme activity? | Point-mutation knock-in of patient variants in cell lines or mice |
| Does overexpression of SRD5A3 drive castration resistance? | SRD5A3 overexpression in prostate cancer cell lines and xenografts |
| What is the role of phosphorylation in regulating enzyme activity? | Phospho-mimetic or phospho-deficient point mutations in SRD5A1 |
| How does the phospholipid environment affect enzyme function? | Knockout of lipid-modifying enzymes combined with lipidomics |
| Can tagged SRD5A2 be used to study localization? | Tagged knock-in of SRD5A2 with fluorescent or affinity tags |
How to Study the 3-oxo-5-alpha-steroid 4-dehydrogenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled substrate assay | Enzyme activity converting testosterone to DHT | Characterizing isozyme kinetics and inhibitor efficacy |
| RNA-seq | mRNA expression levels of SRD5A genes | Tissue-specific expression and cancer profiling |
| Western blot | Protein abundance of 5-alpha-reductase isozymes | Validating knockout or overexpression models |
| Immunohistochemistry | Tissue localization of enzyme protein | Prostate and epididymis studies |
| CRISPR knockout screening | Genes required for enzyme activity or DHT production | Identifying modifiers of androgen metabolism |
| Phosphorylation analysis | Post-translational modification state | Studying regulation of enzyme activity |
| Lipidomics | Membrane phospholipid composition | Correlating lipid environment with enzyme activity |
| Xenograft models | Tumor growth in response to enzyme modulation | Testing SRD5A3 overexpression in prostate cancer |
Enzyme activity assays
Direct measurement of 3-oxo-5-alpha-steroid 4-dehydrogenase activity can be performed using radiolabeled substrates such as testosterone, followed by thin-layer chromatography or HPLC to separate and quantify products. This approach has been used to characterize rat epididymal and liver enzyme activities. Assays can be adapted to high-throughput formats for inhibitor screening.
Gene expression analysis
RNA-seq and quantitative RT-PCR can measure the expression levels of SRD5A1, SRD5A2, and SRD5A3 in tissues and cell lines. This is particularly useful for studying overexpression in prostate cancer and developmental regulation in the epididymis. Single-cell RNA-seq can reveal cell-type-specific expression patterns.
Protein detection and localization
Western blotting and immunohistochemistry with antibodies against 5-alpha-reductase isozymes allow detection and localization of the proteins in tissues. Tagged knock-in models expressing fluorescently labeled enzymes enable live-cell imaging to study subcellular localization and dynamics.
CRISPR screening and functional genomics
Genome-wide CRISPR knockout screens can identify genes that modulate 5-alpha-reductase activity or its downstream effects. Focused libraries targeting steroid metabolism genes can uncover synthetic lethal interactions with SRD5A inhibition. These methods are complemented by bioinformatics analysis of transcriptomic and proteomic data.
How CRISPR Can Be Used to Study GO:0003865 3-oxo-5-alpha-steroid 4-dehydrogenase activity
Knockout
CRISPR-Cas9 knockout of SRD5A1, SRD5A2, or SRD5A3 in cell lines and animal models eliminates enzyme activity, allowing researchers to study the consequences of loss of function. For example, SRD5A2 knockout in prostate cells reduces DHT production and androgen receptor signaling. Knockout models are essential for validating the role of specific isozymes in disease.
Point Mutation
Point mutations can be introduced into SRD5A genes to mimic naturally occurring variants or to dissect catalytic residues. For instance, mutations in SRD5A2 that cause 5-alpha-reductase deficiency can be modeled to understand structure-function relationships. Phospho-mimetic or phospho-deficient mutations in SRD5A1 can test the role of phosphorylation in enzyme regulation.
Knock-in
Knock-in of tagged versions of SRD5A enzymes (e.g., GFP or HA tags) enables visualization and affinity purification of the proteins. Knock-in of reporter genes under the control of endogenous SRD5A promoters can monitor expression dynamics. These models are valuable for studying localization and interaction partners.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can drive high-level expression of SRD5A3 to model hormone-refractory prostate cancer. Overexpression of SRD5A2 in cell lines can increase DHT production and mimic hyperplastic conditions. These models are used to test inhibitors and study downstream signaling.
How EDITGENE Supports 3-oxo-5-alpha-steroid 4-dehydrogenase activity Research
Researchers studying 3-oxo-5-alpha-steroid 4-dehydrogenase activity-related genes often need to determine whether a candidate gene is causally involved in steroid metabolism, disease progression, or drug response. EDITGENE provides a comprehensive suite of CRISPR-based services to generate precisely engineered cell models, enabling rigorous functional validation of SRD5A genes and their regulators.
Contact EDITGENE today to design your custom CRISPR model for 3-oxo-5-alpha-steroid 4-dehydrogenase activity research.
Frequently Asked Questions About 3-oxo-5-alpha-steroid 4-dehydrogenase activity
What is 3-oxo-5-alpha-steroid 4-dehydrogenase activity?
It is an enzymatic activity (GO:0003865) that catalyzes the conversion of a 3-oxo-5-alpha-steroid to a 3-oxo-delta(4)-steroid using an acceptor, commonly known as steroid 5-alpha-reductase.
What genes are involved in 3-oxo-5-alpha-steroid 4-dehydrogenase activity?
The main human genes are SRD5A1, SRD5A2, and SRD5A3, which encode different isozymes of steroid 5-alpha-reductase.
What is the function of steroid 5-alpha-reductase?
It converts testosterone to dihydrotestosterone (DHT), a potent androgen that drives prostate growth and male sexual differentiation.
How is 3-oxo-5-alpha-steroid 4-dehydrogenase activity regulated?
It is regulated by phosphorylation state and the phospholipid environment of the membrane, as well as by developmental and hormonal signals.
What diseases are associated with 5-alpha-reductase activity?
Benign prostatic hyperplasia, prostate cancer, and 5-alpha-reductase deficiency are linked to altered activity of this enzyme.
What is the role of SRD5A3 in prostate cancer?
SRD5A3 is overexpressed in hormone-refractory prostate cancer and may contribute to resistance to androgen deprivation therapy.
How can I study 3-oxo-5-alpha-steroid 4-dehydrogenase activity in the lab?
Common methods include radiolabeled substrate assays, RNA-seq, Western blotting, and CRISPR knockout models.
What are 5-alpha-reductase inhibitors?
Drugs such as finasteride and dutasteride that inhibit the enzyme activity and are used to treat benign prostatic hyperplasia and prostate cancer.
Is 3-oxo-5-alpha-steroid 4-dehydrogenase activity found in bacteria?
Yes, a homolog exists in Comamonas testosteroni, known as 3-ketosteroid-delta4(5-alpha)-dehydrogenase, which has been characterized.
How does phosphorylation affect 5-alpha-reductase?
Changes in phosphorylation state can modulate enzyme activity, as demonstrated for the rat liver enzyme.
Conclusion
3-oxo-5-alpha-steroid 4-dehydrogenase activity (GO:0003865) is a fundamental enzymatic function in steroid metabolism, responsible for converting testosterone to the more potent androgen DHT. Its dysregulation is central to benign prostatic hyperplasia and prostate cancer, making it a key therapeutic target. The activity is regulated by phosphorylation and membrane lipids, and its genetic basis involves the SRD5A gene family. Continued research using CRISPR models and advanced screening methods will further elucidate its roles in health and disease.
References
- 1. Madersbacher S et al.. 2019. Pathophysiology of Benign Prostatic Hyperplasia and Benign Prostatic Enlargement: A Mini-Review.. Gerontology 65(5):458-464 PMID: 30943489
- 3. Golf SW et al.. 1984. Rat liver 3-oxo-5 alpha-steroid delta 4-dehydrogenase. Modulation of enzyme activity by changes in phosphorylation state.. J Clin Chem Clin Biochem 22(11):705-9 PMID: 6527091
- 4. Scheer H et al.. 1980. Steroid delta 4-5 alpha-reductase and 3 alpha-hydroxysteroid dehydrogenase in the rat epididymis during development.. Endocrinology 107(4):948-53 PMID: 6931815
- 5. Yang JC et al.. 2017. Adjunct Screening of NKX3.1 Expression Supports 5α-Reductase Inhibition Intervention in Prostate Cancer Active Surveillance.. Eur Urol 72(4):507-508 PMID: 28454662
- 6. Florin C et al.. 1996. Comamonas testosteroni 3-ketosteroid-delta 4(5 alpha)-dehydrogenase: gene and protein characterization.. J Bacteriol 178(11):3322-30 PMID: 8655514
- 7. Uemura M et al.. 2008. Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer.. Cancer Sci 99(1):81-6 PMID: 17986282
- 8. Cooke GM et al.. 1985. Modulation of epididymal delta 4-steroid 5 alpha-reductase activity in vitro by the phospholipid environment.. J Biol Chem 260(12):7489-95 PMID: 3997884
